ANI Pharmaceuticals received final FDA approval for its ANDA and launched Isosorbide Mononitrate Tablet USP (10). This routine generic product launch should modestly expand ANIP's portfolio and revenue potential but is unlikely to have a material impact on the broader market or sector.
ANI Pharmaceuticals received final FDA approval for its ANDA and launched Isosorbide Mononitrate Tablet USP (10). This routine generic product launch should modestly expand ANIP's portfolio and revenue potential but is unlikely to have a material impact on the broader market or sector.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.12
Ticker Sentiment
